Ondansan

Quick links to important sections

Ondansan

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ondansan

Quick Facts

Property Description
Active ingredient Ondansetron
Form Tablets, orally disintegrating tablets (ODTs), solution for injection
Pharmacological class Anti-emetic, 5-HT3 receptor antagonist
General purpose Management of nausea and vomiting
Origin Synthetic

What Type of Medicine is Ondansan (Ondansetron)?

Ondansan is a prescription-only medication containing the active substance Ondansetron, which is internationally recognized for its powerful action against sickness. The drug is classified as an anti-emetic and, more specifically, belongs to the group of selective Serotonin 5-HT3 receptor antagonists. This pharmacological classification is supported by extensive pharmacological studies confirming its efficacy in controlling symptoms. This specific targeting mechanism defines the drug's role in precisely intercepting pathways responsible for activating the body's sickness response.

Is Ondansetron a Natural or Synthetic Compound?

Ondansetron is a synthetic small molecule, chemically described as a carbazole derivative, and is prepared exclusively as a single-ingredient product. The medicine is supplied in various drug forms, which include conventional tablets, orally disintegrating tablets (ODTs), and solutions for injection. These 5-HT3 antagonists are established agents for emesis control in patients experiencing highly stimulating systemic triggers. This compositional versatility dictates its possible methods of administration, allowing for both convenient oral administration and rapid, effective parenteral administration via injection into a vein or muscle.

What is the General Purpose of an 5-HT3 Antagonist?

The general therapeutic purpose of a 5-HT3 receptor antagonist is the robust management and suppression of intense nausea and vomiting by means of selective antagonism. For example, it is typically used in clinical settings to prevent discomfort following procedures known to be emetogenic. This functional benefit is achieved by blocking the action of serotonin at specific receptor sites, which are critical messengers for triggering the emetic reflex. Ondansetron is a standard inclusion on the World Health Organization's List of Essential Medicines, confirming its established role as a key agent for alleviating acute sickness.

Regulatory References

  1. Ondansetron: MedlinePlus Drug Information
  2. Ondansetron on WHO Model List of Essential Medicines

What side effects are possible with Ondansan?

Possible Side Effects and Safety Information

The safety profile for Ondansetron (Ondansan) is documented by health authorities, classifying potential adverse reactions by frequency and the body system affected. These classifications establish the known risks, ranging from commonly reported events to rare, clinically significant concerns.

Adverse Reactions and Frequency

Adverse effects are categorized according to the frequency observed in clinical use. Very Common events (ge 1/10) include headache. Reactions classified as Common (ge 1/100 to < 1/10) include constipation and sensations of flushing or warmth.

Less frequently reported events, categorized as Uncommon or Rare, involve physiological systems such as the nervous system, with reports of seizures and involuntary movement disorders, and the visual system, with occasional transient visual disturbances.

Serious Adverse Reactions and Safety Constraints

The official safety information highlights the risk of QT interval prolongation, which is a dose-dependent effect that increases the possibility of a serious heart rhythm irregularity, Torsade de Pointes. Cases of Serotonin Syndrome have also been reported when Ondansetron is used concurrently with other serotonergic agents. Hypersensitivity reactions, including anaphylaxis, are also documented safety concerns.

Official labeling defines strict limitations for use. For instance, concomitant use with apomorphine is explicitly contraindicated due to the risk of profound hypotension and loss of consciousness. Dose adjustment is specifically addressed for patients with severe hepatic impairment, where the body's clearance of the medicine is significantly reduced.

Overdose and Emergency Response

Overdose and When to Seek Help

A suspected overdose of Ondansan (Ondansetron) requires immediate contact with emergency medical services or a regional poison control center, as officially mandated by regulatory authorities.


Documented Manifestations and Risks

Overdose events are documented to affect primarily the cardiovascular and central nervous systems. Manifestations may include transient visual disturbances, severe constipation, hypotension, and a vasovagal episode with transient second-degree atrioventricular block. More serious or life-threatening outcomes reported in regulatory documents include cardiac arrest and Torsade de Pointes, a potentially fatal ventricular arrhythmia, which is linked to dose-dependent QTc prolongation. Accidental overdose in young children has been associated with severe toxicity, including deep sedation and seizures, and symptoms consistent with Serotonin Syndrome.


Emergency Actions and Management

Regulatory guidance explicitly states that immediate medical attention must be sought for a suspected overdose, even if the individual appears asymptomatic. Immediate help is also required if signs such as irregular heartbeat or fainting occur. Due to the high risk of serious cardiac events, continuous ECG monitoring is recommended in a clinical setting. Management is strictly procedural: there is no specific antidote known for Ondansetron overdose, and regulatory documents confirm the approach is confined to providing symptomatic and supportive treatment under medical supervision.

Therapeutic Uses of Ondansan

What Ondansan Treats: Main Uses and Benefits

Ondansetron is commonly used to help with symptoms related to heightened physiological activity and is applied in addressing acute or episodic changes. It is commonly used to help with sickness associated with cancer treatment, radiation therapy, and surgery. It supports general well-being during symptomatic phases and contributes to improved comfort during periods of heightened symptoms.


This medication may be part of symptomatic management when conditions involve specific manifestations: Chemotherapy-Induced Nausea and Vomiting (CINV), Radiation-Induced Nausea and Vomiting (RINV), and Postoperative Nausea and Vomiting (PONV). It is considered relevant for easing symptoms that become more disruptive during flare-ups, such as sickness associated with pregnancy-related nausea. It is applied in addressing symptom clusters that may become intense or disruptive, especially when sickness interferes with daily comfort.

Quick Fact: Relief for Symptoms Related to Physical Discomfort

Property Description
Main Focus Symptoms related to physical discomfort
Primary Contexts Applied in clinical settings that involve acute or unstable symptom patterns
Core Benefit Supports the patient during difficult episodes by easing distress

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Official Eligibility Status for Ondansan (Ondansetron)

The official regulatory profile defines eligibility for Ondansan based on mandatory contraindications and specific patient characteristics, establishing precise boundaries for its use.

Category Eligibility Rule (Regulatory Basis)
Absolute Contraindications Use is forbidden in patients with known hypersensitivity to the medicine or who are receiving concomitant apomorphine. It is also contraindicated in patients with congenital long QT syndrome (a specific heart condition).
Age-Group Eligibility The medicine is approved for use in adults. Pediatric use for chemotherapy-related sickness is established in children aged 6 months and older, and for postoperative sickness in children aged 1 month and older (typically via injection).
Organ Function Restriction A total daily dose must not exceed 8 mg for patients with severe hepatic impairment. No alteration of daily dosage or frequency is generally required for patients with renal impairment.
Conditional Use & Caution Caution is required in patients with or at risk for QTc prolongation, including those with cardiac failure or electrolyte abnormalities. Use is conditional during pregnancy (considered only after failure of other therapies) and is generally not recommended while breastfeeding.

This eligibility profile is structured by mandatory exclusions and precise age- and condition-based limitations, detailing who can and cannot use the drug based solely on official regulatory standards.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Ondansan (Ondansetron) is defined by required restrictions and pharmacokinetic limitations documented in regulatory labeling.

Contraindicated Combinations

Co-administration with Apomorphine is strictly prohibited as documented in the official prescribing information, due to the established risk of profound hypotension and loss of consciousness.

Pharmacodynamic Interactions

Use with other Serotonergic drugs (such as SSRIs, SNRIs, MAOIs, Tramadol, and Methylene Blue) carries a heightened, additive risk of developing Serotonin Syndrome. Additionally, combining Ondansetron with any medication known to prolong the cardiac QT interval increases the documented risk of QT prolongation and Torsade de Pointes.

Pharmacokinetic Interactions

Ondansetron is a substrate for multiple hepatic enzymes, predominantly CYP3A4. Potent CYP3A4 Inducers—including Phenytoin, Carbamazepine, and Rifampin—significantly increase the clearance of Ondansetron. This metabolic interaction leads to decreased Ondansetron blood concentrations and reduced systemic exposure.

Other Documented Interaction Notes

  • Food: Oral bioavailability is slightly enhanced by the presence of food.
  • Population Specificity: Severe Hepatic Impairment results in substantially decreased plasma clearance and a prolonged half-life.
  • Product Caution: The orally disintegrating tablet (ODT) formulation contains Aspartame, which requires caution for patients with Phenylketonuria (PKU).

Mechanism of Action

Ondansetron, the active substance in Ondansan, functions through a highly specific pharmacological action to modulate afferent neural signaling associated with the emetic reflex.

Selective Blockade of the 5-HT3 Receptor

The drug's primary mechanism involves the selective antagonism of the Serotonin 5-HT3 receptor. By binding to this molecular target, Ondansetron prevents the neurotransmitter Serotonin (5-HT) from activating the receptor, which is an ion channel. This specific interaction immediately suppresses the electrical signal that would otherwise be transmitted along the nerve, which limits subsequent neuronal firing.

Dual Interruption of the Emetic Reflex Cascade

Ondansetron modulates the emetic reflex arc through a dual action on two critical sites. It blocks 5-HT3 receptors on the vagal afferent nerve endings in the gut (peripheral action) and in the Chemoreceptor Trigger Zone (CTZ) of the brainstem (central action). This simultaneous blockade ensures the emetic signal is intercepted both at its point of peripheral origin and at its central processing hub, which significantly reduces the excitatory input to the brain's Vomiting Center.

Mechanistic Constraint to Serotoninergic Pathways

The drug's mechanism is rigidly constrained to the 5-HT3 pathway, meaning it lacks significant affinity for other major signaling systems, such as the dopamine D2 or vestibular (Histamine H1) pathways. This specificity results in a highly targeted physiological effect on 5-HT-mediated signaling, but limits the drug's ability to modulate physiological responses driven predominantly by these non-targeted neurotransmitter systems.

Dosage and Administration Information

Ondansetron is used in clinical practice through multiple administration routes, including oral (tablets, solution, orally disintegrating tablets) and parenteral via intravenous (IV) or intramuscular (IM) injection. The medicine is administered using a prophylactic schedule, meaning the initial dose must be taken before the emetogenic stimulus, such as 30 minutes prior to chemotherapy or 1 hour before anesthesia induction.

Standard adult oral dosing varies by the anticipated severity of the sickness. For prevention of sickness associated with highly emetogenic chemotherapy, a single 24 mg oral dose is utilized. For moderately emetogenic chemotherapy, a divided regimen begins with an 8 mg oral dose, followed by a repeat dose 8 hours later. The maximum recommended total daily oral dose is strictly constrained to 24 mg.

Specific requirements govern the administration of different formulations. Oral forms may be taken with or without food. Orally disintegrating tablets (ODTs) must be handled with dry hands, peeled from the foil backing, and allowed to dissolve on the tongue; they must not be swallowed whole. For IV administration, higher doses for chemotherapy must be diluted in 50 mL of compatible fluid and infused slowly over 15 minutes. Official guidelines mandate a total daily dose not to exceed 8 mg for patients with severe hepatic impairment, while no dosage alteration is required for renal impairment. Treatment is generally short-term, typically continuing for only one to five days after the initiating procedure.

Recent Clinical Evidence

Research evidence / Overview of Studies for Ondansan

Evidence for use in Managing Sickness from Chemotherapy (CINV)

Research was conducted to study the patterns of sickness and vomiting that can follow cancer treatment, focusing on patients receiving chemotherapy known to cause moderate or severe sickness. The main outcomes studied included tracking nausea severity and recording the number of times a patient experienced vomiting or required additional anti-sickness medicine.

Research explored whether the medication was studied for modulating these symptoms during the acute phase (the first 24 hours after chemotherapy) and the delayed phase (up to five days after treatment). These studies contribute to the broader evidence landscape regarding managing episodic or acute changes in symptom patterns.

The long-term effects are not fully established, and symptom patterns extending beyond the typical five-day observation period are not fully characterized. While studies included pediatric populations, the data for certain groups remain insufficient compared to the large body of evidence available for adults.


Evidence for use in Preventing Sickness After Surgery (PONV)

Research was conducted for examining symptoms following surgical procedures under general anesthesia. Randomized Controlled Trials (RCTs) and pooled meta-analyses were applied in studies examining short-term symptom patterns in both adult and pediatric patients. These studies explored outcomes related to physical discomfort and tracked whether patients experienced sickness or vomiting in the first hours and days after their procedure.

Findings describe patterns observed in the studies regarding the use of the medicine before the end of surgery, and how post-operative symptoms were measured following this administration. Findings reported outcomes predominantly for the prevention of symptoms, rather than for the treatment of established, breakthrough sickness.


Research in Special Patient Populations

Research was evaluated in pediatric patients, including infants as young as one month, primarily in the contexts of studying symptom patterns after surgery and after chemotherapy. Studies monitored outcomes related to physiological strain or stress in these younger populations over short time intervals. Studies explored how symptoms evolved in older adults in trials alongside the general adult population.

The research exploring sickness associated with pregnancy was observed in large observational cohorts and systematic reviews. The primary outcomes studied were long-term birth outcomes, including the incidence of congenital malformations and fetal death. Findings were mixed regarding specific birth outcomes. Certainty remains low due to these conflicting results across different large population studies, and the scientific literature indicates that research is ongoing to fully clarify these potential long-term outcomes.

Key Studies & References

  1. Ondansetron - StatPearls [Internet] - NCBI Bookshelf
  2. Risk of abnormal pregnancy outcomes after using ondansetron during pregnancy: A systematic review and meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Ondansan (FAQ)

Q: Can Ondansan be taken with pain relievers like ibuprofen or acetaminophen?

A: Official product information for Ondansan lists specific drug classes that can interact, such as medicines that prolong the heart's QT interval or affect serotonin levels. Common non-opioid pain relievers (e.g., ibuprofen or acetaminophen) are not typically listed in the known interaction warnings related to QT prolongation or serotonin levels.

Q: Can a history of heart issues affect whether you can take Ondansan?

A: Official safety information states that Ondansan is contraindicated (use is generally forbidden) if a person has congenital long QT syndrome, which is a specific heart condition. Caution and monitoring may also be advised for individuals with heart failure, a slow heart rate, or electrolyte imbalances, as these conditions can increase the risk of a heart rhythm irregularity.

Q: Does Ondansan interact with common allergy medications (antihistamines)?

A: Regulatory information indicates that Ondansan can interact with any medicine that has the potential to prolong the heart's QT interval. While not all antihistamines are specifically named, official information advises caution regarding all concomitant medications that carry a risk of QT interval prolongation.

Q: What is the longest period of time you can safely take Ondansan?

A: Official guidance defines dosing schedules for short-term treatments, such as for 1 to 5 days following chemotherapy or surgery. The drug is indicated and dosed primarily for acute and short-term use in clinical settings. Regulatory documents do not provide a defined maximum duration for chronic, long-term use.

Q: Does Ondansan cause constipation, and is that a common problem?

A: Yes, official regulatory documents list constipation as a common side effect reported by patients in clinical studies.

Q: Can I take Ondansan if I am already taking blood pressure medication?

A: Ondansan is strictly contraindicated (use is forbidden) with apomorphine, a medicine that can affect blood pressure. The interaction profile warns against all heart-related medications that may increase the risk of an irregular heart rhythm (QT prolongation).

Q: Can I take Ondansan if I have a history of liver problems?

A: Official product information states that for individuals with severe hepatic impairment (severe liver problems), the total daily dose must be lowered. Official information indicates that no dose adjustment is generally required for patients with renal impairment or for non-severe hepatic impairment.

Q: Does Ondansan interact with herbal supplements like ginger or St. John's Wort?

A: The drug is known to interact with strong CYP3A4 inducers, which are medicines that increase the breakdown of Ondansan in the body. Official warnings cover potent CYP3A4 inducers, like Phenytoin and Carbamazepine. Since St. John's Wort is also known to induce this enzyme, it carries a potential risk for the same metabolic interaction.

Q: Is Ondansan effective for severe morning sickness in pregnancy (general question)?

A: Official guidance restricts the use of Ondansan during pregnancy, typically limiting it to situations where other anti-nausea treatments have failed. Research on specific long-term birth outcomes has shown mixed results, and official certainty regarding these outcomes remains low.

Q: Is it okay to crush or chew the Ondansan tablet if I have trouble swallowing?

A: Official administration instructions vary by tablet type. If the product is the orally disintegrating tablet (ODT), it is designed to be allowed to dissolve on the tongue and must not be swallowed whole. The regular tablet form is generally intended to be swallowed whole.

Q: Why do some people experience dry mouth after taking Ondansan?

A: Although dry mouth is not listed as one of the most common side effects, it has been reported in postmarketing experience (after the drug was released) and is noted in some regulatory documents.

Q: Why is my prescription for Ondansan labeled 'as needed'?

A: The official use of Ondansan is primarily for the prevention of sickness before an event (like chemotherapy) or for short-term treatment of symptoms. For certain situations, such as preventing nausea after surgery, routine use is not recommended unless a patient is at high risk, which supports the use of the drug only 'as needed' when symptoms arise.

Q: What happens if you miss a dose of Ondansan?

A: If a dose is missed, patient information suggests taking it as soon as it is remembered. However, if it is almost time for the next scheduled dose, skip the missed dose and continue with the regular schedule. A double dose should not be taken to make up for a single missed dose.

Q: How long do the effects of one Ondansan tablet usually last?

A: The medicine is eliminated from the body with an approximate half-life of 4 hours. Dosing schedules for moderately emetogenic procedures are often spaced 8 hours apart, which suggests a clinical duration of action intended to cover that required time window.

Q: Does Ondansan affect your mood or cause anxiety?

A: Adverse reaction reports have included mood changes, anxiety, and agitation. Additionally, a rare but serious risk is Serotonin Syndrome, which includes severe changes to mental status such as agitation and delirium.

Q: Is it safe to drive after taking a regular dose of Ondansan?

A: Side effects like dizziness or drowsiness have been reported with this medication. Official information advises that if a person experiences these effects, the ability to drive or operate machinery may be impaired.

Q: Are there any long-term side effects associated with Ondansan use?

A: Regulatory documents list a wide range of known side effects, but the drug is primarily prescribed for short-term use. The safety profile for chronic, daily use over extended periods of time is not fully established in the primary regulatory indications.

Q: What should I do if my nausea doesn't go away after taking Ondansan?

A: Ondansan is approved for the prevention of sickness related to specific events and may not be effective for all types of nausea. If symptoms persist or worsen after taking the authorized dose, it indicates that the effectiveness of the current treatment approach may need to be assessed.

Q: Are there any less common, but serious, side effects of Ondansan I should know about?

A: Yes, serious adverse reactions documented in official warnings include a risk of an irregular heart rhythm (QT prolongation), Serotonin Syndrome, and severe allergic reactions (hypersensitivity) such as anaphylaxis.

Q: Does Ondansan stop nausea immediately or does it take time?

A: Ondansan is typically administered on a prophylactic schedule, meaning it is taken before the event that causes sickness to prevent it. Following an oral dose, the highest concentration in the blood is reached in about 1.5 hours, indicating the drug is not an immediate-action medication.

Q: What is the success rate of Ondansan in clinical trials for nausea prevention?

A: Official regulatory labels include specific data from clinical studies showing the percentage of patients who achieved success, often defined as no emetic episodes. The documented success rates vary depending on the type of procedure or the severity of the chemotherapy regimen being studied.

Q: Are there specific symptoms that mean I should stop taking Ondansan right away?

A: Official warnings list serious symptoms that require urgent attention, such as signs of a severe allergic reaction (like swelling or difficulty breathing), symptoms of Serotonin Syndrome, or an irregular or rapid heartbeat.

Q: Does Ondansan interact with alcohol, and what are the risks?

A: Regulatory documents do not list a direct chemical interaction between Ondansan and alcohol. However, because the medication can cause side effects like dizziness and drowsiness, consuming alcohol may increase the likelihood and severity of these central nervous system effects.

Q: Is a metallic taste in the mouth a known side effect of Ondansan?

A: While not a common side effect, taste disturbances, including an altered or metallic taste, have been reported rarely in postmarketing experience, according to official regulatory documents.

Q: If I am sensitive to other medicines, is Ondansan likely to cause side effects?

A: Official warnings note that patients who have experienced a severe allergic reaction (hypersensitivity) to other drugs in the same class (selective 5-HT3 receptor antagonists) may have an increased risk of similar reactions with Ondansan.

Q: Is Ondansan only available by prescription, or can you buy it over the counter?

A: Ondansetron, the active ingredient in Ondansan, is classified as a prescription-only medication in most major territories, meaning it is not available for purchase over the counter.

Q: Does Ondansan interact with antidepressants or mood stabilizers?

A: Yes, official safety information highlights that taking Ondansan with other serotonergic drugs, which include many antidepressants (like SSRIs and SNRIs), carries an increased risk of developing Serotonin Syndrome.

Q: Is there a maximum number of days you should take Ondansan in a row?

A: Official guidance defines dosing schedules for short-term treatments, such as for 1 to 5 days following chemotherapy or surgery. The drug is indicated and dosed primarily for acute and short-term use in clinical settings. Regulatory documents do not provide a defined maximum duration for chronic, long-term use.

Q: Does taking Ondansan affect physical performance or exercise?

A: Reported side effects of the medication include fatigue, malaise, and dizziness. Experiencing these effects may temporarily affect an individual's physical performance or ability to exercise.

How should Ondansan be stored and disposed of?

Ondansetron must be stored and handled according to specific regulatory requirements to maintain product stability and safety.

Storage Conditions

Form Temperature Requirement Environmental Constraints
Oral Forms (Tablets/Solution) Store at controlled room temperature (20 C to 25 C) Protect from light and moisture
Injection (Undiluted Vial) Store between 2 C and 30 C Must not be frozen; store in the original carton to protect from light

Orally Disintegrating Tablets (ODTs) must remain sealed in the foil blister packaging until use to protect them from moisture. The diluted injection solution, when prepared with compatible intravenous fluids, is chemically and physically stable for 48 hours at room temperature.

Child-Safety and Disposal

All forms of this medicine must be stored out of the sight and reach of children. Unused or expired Ondansetron must be handled as pharmaceutical waste and disposed of in accordance with local requirements. Official guidelines state that the medicine should not be disposed of via wastewater or household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ondansan found in:

A-Z Index: